Zogenix — Merger or Acquisition (August 2019)
14 slides from Zogenix's merger presentation, Aug 26, 2019
Slide 1: Acquisition of Modis Therapeutics Investor Conference Call
Acquisition of Modis Therapeutics August 26, 2019 Investor Conference Call Exhibit 99.2
Slide 2: Forward-looking statements
Zogenix cautions you that statements included in this presentation that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will,“ "intends," "potential," "suggests," "assuming," "designed" and similar e
Slide 3: Advancing Our Mission in Rare Disease
Advancing Our Mission in Rare Disease Acquisition of Modis Therapeutics Zogenix is a pharmaceutical company dedicated to providing transformative therapeutic solutions to patients and their families living with serious rare diseases
Slide 4: Strategic Opportunities Criteria
Strategic Opportunities Criteria Serious Rare Disease Limited or Ineffective Treatment Options Development Stage, High ROI Potential Leverages Development and Commercial Rare Disease Expertise Breakthrough Therapeutic Potential
Slide 5: Rare Disease Therapy Expertise
Rare Disease Therapy Expertise MT1621 Breakthrough Clinical Proof-of-Concept established by leading KOLs Breakthrough Clinical Proof-of-Concept established by leading KOLs Acquisition of Business Venture, Intellectual Property Acquisition of Business Venture, Intellectual Property Drive to deliver p
Slide 6: Thymidine Kinase (TK2) Deficiency
222 Thymidine Kinase 2 (TK2) Deficiency Presents as progressive, severe muscle weakness Profoundly impairs movement, breathing, eating, etc. Symptom onset can start as early as the first year of life Onset early in life predicts faster progression of disease Patients most often die from respiratory
Slide 7: MT1621 dC/dT Substrate Enhancement Therapy
MT1621 dC/dT Substrate Enhancement Therapy Nucleosides Prolong Survival in TK2d Mouse Models(1): (1) Lopez-Gomez et al. Ann Neurol 2017 TK2 phosphorylates deoxycytidine (dC) and deoxythymidine (dT), fundamental building blocks in production of mitochondrial DNA (mtDNA) MT1621, orally administered dC
Slide 8: MT1621 Clinical Efficacy RETRO Study
MT1621 Clinical Efficacy RETRO Study Modified Untreated Dataset n=68 Sourced from natural history publications & additional updates Characterizes course of untreated disease Serves as matched age comparator for patient survival analysis Eight clinical sites in U.S., Spain, and Israel Patient set rep
Slide 9: MT1621 RETRO Study Preliminary Data
MT1621 RETRO Study Preliminary Data Survival difference between treated patients in RETRO study and untreated patients (TK2d Natural History data set) is statistically significant (p<0.004). Kaplan-Meier Survival Analysis, All Age Groups: Treated vs. Modified Untreated Group (matched patient natural
Slide 10: MT1621 Development Plan
MT1621 Development Plan RETRO - Retrospective treatment study using Natural History as control – Complete 38 patients: ~80 patient years total exposure Prospective continuation study for RETRO patients and new patients – Initiated Q3 2019 Avg of 6 months Measure ongoing efficacy, safety and tolerabi
Slide 11: Transaction Terms and Financial Implications
Transaction Terms and Financial Implications Consideration $250M upfront ($175M in cash, $75M in Zogenix stock) Up to $150M related to regulatory approvals for MT1621 ($100M for U.S. approval, $50M for E.U. approval) 5% of net sales of MT1621 Source of Upfront Cash Payment $460M in cash, mkt. securi
Slide 12: Expanding Rare Disease Pipeline
Expanding Rare Disease Pipeline Product/Platform Discovery Preclinical Phase 1 Phase 2 Phase 3 Regulatory Fenfluramine Dravet Syndrome Lennox-Gastaut Syndrome Doose Syndrome, Other Rare Epilepsies Thymidine Kinase 2 (TK2) Deficiency TK2 Deficiency Registration Trial MT1621 Pyrimidine deoxynucleoside
Slide 13: Continuing Momentum: Upcoming Milestones
Continuing Momentum Upcoming Milestones Anticipated Date FINTEPLA: US NDA and EU MAA submissions in Dravet syndrome Q1 2019 FINTEPLA: Exclusive distribution agreement in Japan (Nippon Shinyaku) Q1 2019 FINTEPLA: US FDA Type A meeting following RTF letter Q2 2019 FINTEPLA: Complete enrollment of glob
Slide 14: Q&A
Q&A ZOGENIX